Gilead and Arcellx advance CAR T partnership in multiple myeloma

Gilead Sciences and Arcellx continue to progress their collaboration focused on developing innovative cell therapies for multiple myeloma, with growing attention on their lead CAR T candidate. The partnership, originally established to accelerate next generation treatments, combines Arcellx’s ARC SparX platform with Gilead’s global development and commercial expertise.

The lead programme, anitocabtagene autoleucel, is being evaluated in clinical studies targeting patients with relapsed or refractory multiple myeloma. Early data have suggested encouraging efficacy and a potentially improved safety profile compared with earlier CAR T approaches, particularly in reducing treatment related toxicities.

Both companies have highlighted the therapy’s potential to address unmet need in patients who have exhausted standard treatment options. Ongoing trials are expected to further define its clinical benefit and support future regulatory discussions.

The collaboration reflects a broader strategy by Gilead to strengthen its oncology pipeline through partnerships, while Arcellx benefits from expanded resources to advance its platform. Analysts suggest the programme could become a key contender in the evolving CAR T landscape if clinical outcomes continue to meet expectations.